Abstract: Disclosed a pregabalin-containing, high swellable, oral sustained-release triple layer tablet suitable for administration once daily.

Abstract: The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer.

Abstract: Disclosed a pregabalin-containing, high swellable, oral sustained-release triple layer tablet suitable for administration once daily.

Abstract: The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer.

Abstract: This invention relates to a solid dispersion formulation comprising tacrolimus and enteric polymer. The solid dispersion formulation may contribute to better stability of tacrolimus preparation under high temperature and humidity condition through reduced recrystallization rate of tacrolimus. In addition, the solid dispersion formulation releases tacrolimus immediately in aqueous media and elevated solubility level maintains for certain period of time and that way the formulation may also enhance the bioavailability and oral absorption rate of tacrolimus.

Abstract: The present invention relates to a sustained-release tablet containing doxazosin mesylate, and more particularly to a sustained-release tablet of which drug release rate maintains constant for 8 hours and longer.

Abstract: Provided is a controlled-release formulation of tamsulosin hydrochloride, which includes a granular core, and a drug-coating layer coated on the granular core, including the tamsulosin hydrochloride and a release-controlling agent selected from the group consisting of (a) a first copolymer of 1 part by weight of ethylacrylate, 2 parts by weight of methylmethacrylate, and 0.1 parts by weight of trimethylammonioethyl methacrylate chloride, (b) a mixture of the first copolymer and a second copolymer of 1 part by weight of ethylacrylate, 2 parts by weight of methylmethacrylate, and 0.2 parts by weight of trimethylammonioethyl methacrylate chloride, the weight ratio between the first copolymer and the second copolymer being 1: 0.05 to 0.2, and (c) polyvinylacetate. A process for preparing the controlled-release formulation of the tamsulosin hydrochloride is also provided.